Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Usual Type Vulval Intraepithelial Neoplasia (uVIN) 1Condylomata Acuminata 1

Interventions

Cyclophosphamide 741Cisplatin 688Gemcitabine 641Bevacizumab 616Carboplatin 605Paclitaxel 601Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 361Capecitabine 342Filgrastim 333Etoposide 330Dexamethasone 312Irinotecan 309pembrolizumab 282Leucovorin 274Cetuximab 268Cytarabine 242Erlotinib Hydrochloride 231Nivolumab 228Prednisone 227Trastuzumab 225Vincristine 221Bortezomib 221Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Completed × Omiganan × Clear all
NCT02596074 2017-08-03

Pharmacodynamics, Safety/Tolerability and Efficacy of Topical Omiganan in Patients With uVIN

Maruho Co., Ltd.

Phase 2 Completed
12 enrolled

Usual Type Vulval Intraepithelial Neoplasia (uVIN)

NCT02849262 2017-03-31

Pharmacodynamics, Safety and Efficacy of Topical Omiganan in Patients With External Genital Warts

Maruho Co., Ltd.

Phase 2 Completed
24 enrolled

Condylomata Acuminata

Data powered by HemOnc (CC BY 4.0) Colophon âš¡